{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Morpholinodoxorubicin",
  "nciThesaurus": {
    "casRegistry": "89196-04-3",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "A semisynthetic derivative of the anthracycline antineoplastic antibiotic doxorubicin.  As an antineoplastic agent, morpholinodoxorubicin is more potent than doxorubicin.  Similar to doxorubicin, morpholinodoxorubicin intercalates into DNA and causes single- and double-strand breaks in DNA via inhibition of topoisomerase I and II.  Unlike doxorubicin, this agent is metabolized in vivo to a DNA-alkylating derivative that forms DNA interstrand cross-links, thereby potentiating its doxorubicin-like cytotoxicity.",
    "fdaUniiCode": "X0N4EFN4AI",
    "identifier": "C1442",
    "preferredName": "Morpholinodoxorubicin",
    "semanticType": "Antibiotic",
    "subclassOf": [
      "C1594"
    ],
    "synonyms": [
      "5,12-Naphthacenedione, 7, 8, 9, 10-tetrahydro-6, 8, 11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2, 3, 6-trideoxy-3-(4-morpholinyl)-alpha-L-lyxo-hexopyranosyl] oxy]-, hydrochloride, (8S-cis)-",
      "MORPHOLINODOXORUBICIN",
      "Morpholinodoxorubicin",
      "morpholino-ADR",
      "morpholino-adriamycin"
    ]
  }
}